I agree, RW. I wish they would keep supplying this information to patients. We (the communal "we") fought for this drug, AND the PML monitoring process ... so I think they owe us ongong transparency.

It seems they should have patterns established by July 24th though... since they see that as the reason to no longer supply this PML incident information to patients ... then those who are at more risk can weigh up their decision on that basis.

That appears to be a "study" of some sort, possibly sanctioned by Biogen. I'm quite sure that the majority of EX-US patients have NOT used stem cell treatments, and/or that there are no US patients who've used other strong immunosuppressants at some point before Tysabri.

If immunosuppression is a potential risk factor though, can you link to a definition of how long people are supposed to wait/dependant on what drug, before going on Tysabri, Chris? I haven't (personally) seen that criteria detailed even for US patients yet.

It was just a small study, but it is interesting that the results show that THOSE strong immunosuppressants didn't seem to affect the outcome.

I hope they are undergoing bigger (and longer) studies, that might give them more conclusive evidence that immunsuppression either does or doesn't influence the development of PML. Maybe they are waiting on those results as we speak, and that this may be why they think they are getting closer to answers ...

Cherie